ClinicalTrials.gg
CompletedNCT05246072Updated Apr 7, 2022

Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients

A Phase 4 interventional study of Ivermectin + colchicine and Colchicine in COVID-19, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2021, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in COVID-19 by Ain Shams University — 1 open to participants now, 1 under way, none of them phase 3. COVID-19 · Ain Shams University.

Enrollment
5th of 18
135 · median 90
Started
2021
with 11 others
Phase 4
3 of 38
none open now
Registered
29th of 38
by date

Among the 38 studies in COVID-19 by Ain Shams University, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 12 that started in 2021, is one of 3 in phase 4, and was the 29th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 38 studies in COVID-19 by Ain Shams University is open now. Recruiting first, the newest first:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in COVID-19 by Ain Shams University, or all of them as a file.
02

Study summary

The aim of this study will be to investigate the efficacy of use of combination of Ivermectin and colchicine on severity and outcome Of COVID 19 infection.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written prior to performing study procedures.
  • Currently hospitalized and requiring medical care for non-sever COVID-19.
  • One or more of the following: (positive PCR test or positive antibodies) or (CT Chest consistent with COVID19 infection).

Exclusion criteria

Exclusion Criteria:

  • Tocilizumab use.
  • Mechanical ventilation
  • Requirement of oxygen supplementation >8L/min on admission
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Active comparator
    Ivermectin + colchicine + standard care

    In addition to the local standard of care for COVID 19 patients, the patient will receive: Ivermectin + Colchicine

    Drug: Ivermectin + colchicine

  • Active comparator
    Colchicine + standard care

    In addition to the local standard of care for COVID 19 patients, the patient will receive: Colchicine

    Drug: Colchicine

  • No intervention
    standard care

    Patients will receive Standard care

Interventions

  • DrugIvermectin + colchicine

    Drug pages: IvermectinStudies of IvermectinIvermectin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine

  • In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine

06

What researchers measure

Primary outcomes

  1. length of oxygen requirement

    Time frame: 3 months

07

Study locations

1 site
  • Ain Shams University hospitals
    Cairo, 11591, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Feb 2022, 3 months.

Of 145 non-industry phase 4 interventional studies under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 3 months is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Feb 18, 2022
StartActual
Nov 1, 2021
Primary completionActual
Feb 28, 2022
CompletionActual
Feb 28, 2022
Last update
Apr 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05246072
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Nov 1, 2021
Primary completion
Feb 28, 2022
Completion
Feb 28, 2022
Last update
Apr 7, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion